Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.

IF 2.6 3区 生物学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
BioMed Research International Pub Date : 2024-08-06 eCollection Date: 2024-01-01 DOI:10.1155/2024/8182887
Xiaoyan Gai, Xiaoyan Sun, Beibei Liu, Wei Yan, Zikang Sheng, Qingtao Zhou, Yongchang Sun
{"title":"Efficacy of Combination of Antiviral Therapy With Neutralizing Monoclonal Antibodies for Recurrent Persistent SARS-CoV-2 Pneumonia in Patients With Lymphoma.","authors":"Xiaoyan Gai, Xiaoyan Sun, Beibei Liu, Wei Yan, Zikang Sheng, Qingtao Zhou, Yongchang Sun","doi":"10.1155/2024/8182887","DOIUrl":null,"url":null,"abstract":"<p><p>Despite the potential of neutralizing antibodies in the management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), clinical research on its efficacy in Chinese patients remains limited. This study is aimed at investigating the therapeutic effect of combination of antiviral therapy with neutralizing monoclonal antibodies for recurrent persistent SARS-CoV-2 pneumonia in patients with lymphoma complicated by B cell depletion. A prospective study was conducted on Chinese patients who were treated with antiviral nirmatrelvir/ritonavir therapy and the neutralizing antibody tixagevimab-cilgavimab (tix-cil). The primary outcome was the rate of recurrent SARS-CoV-2 infection. Five patients with lymphoma experienced recurrent SARS-CoV-2 pneumonia and received tix-cil treatment. All patients had a history of CD20 monoclonal antibody use within the year preceding SARS-CoV-2 infection, and two patients also had a history of Bruton's tyrosine kinase (BTK) inhibitor use. These patients had notably low lymphocyte counts and exhibited near depletion of B cells. All five patients tested negative for serum SARS-CoV-2 IgG and IgM antibodies. None of the patients developed reinfection with SARS-CoV-2 pneumonia after antiviral and tix-cil treatment during the 6-month follow-up period. In conclusion, the administration of antiviral and SARS-CoV-2-neutralizing antibodies showed encouraging therapeutic efficacy against SARS-CoV-2 pneumonia in patients with lymphoma complicated by B cell depletion, along with the potential preventive effect of neutralizing antibodies for up to 6 months.</p>","PeriodicalId":9007,"journal":{"name":"BioMed Research International","volume":"2024 ","pages":"8182887"},"PeriodicalIF":2.6000,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11321881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioMed Research International","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1155/2024/8182887","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Despite the potential of neutralizing antibodies in the management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), clinical research on its efficacy in Chinese patients remains limited. This study is aimed at investigating the therapeutic effect of combination of antiviral therapy with neutralizing monoclonal antibodies for recurrent persistent SARS-CoV-2 pneumonia in patients with lymphoma complicated by B cell depletion. A prospective study was conducted on Chinese patients who were treated with antiviral nirmatrelvir/ritonavir therapy and the neutralizing antibody tixagevimab-cilgavimab (tix-cil). The primary outcome was the rate of recurrent SARS-CoV-2 infection. Five patients with lymphoma experienced recurrent SARS-CoV-2 pneumonia and received tix-cil treatment. All patients had a history of CD20 monoclonal antibody use within the year preceding SARS-CoV-2 infection, and two patients also had a history of Bruton's tyrosine kinase (BTK) inhibitor use. These patients had notably low lymphocyte counts and exhibited near depletion of B cells. All five patients tested negative for serum SARS-CoV-2 IgG and IgM antibodies. None of the patients developed reinfection with SARS-CoV-2 pneumonia after antiviral and tix-cil treatment during the 6-month follow-up period. In conclusion, the administration of antiviral and SARS-CoV-2-neutralizing antibodies showed encouraging therapeutic efficacy against SARS-CoV-2 pneumonia in patients with lymphoma complicated by B cell depletion, along with the potential preventive effect of neutralizing antibodies for up to 6 months.

抗病毒疗法与中和单克隆抗体联合治疗淋巴瘤患者复发性持续性SARS-CoV-2肺炎的疗效。
尽管中和抗体在治疗严重急性呼吸系统综合征冠状病毒-2(SARS-CoV-2)方面具有潜力,但有关其在中国患者中疗效的临床研究仍然有限。本研究旨在探讨抗病毒治疗与中和单克隆抗体联合应用对因B细胞耗竭而并发淋巴瘤的反复持续性SARS-CoV-2肺炎患者的治疗效果。这项前瞻性研究针对接受抗病毒药物尼马瑞韦/利托那韦治疗和中和抗体替沙吉单抗-替加维单抗(tix-cil)治疗的中国患者。主要结果是 SARS-CoV-2 感染的复发率。五名淋巴瘤患者复发了SARS-CoV-2肺炎,并接受了tix-cil治疗。所有患者在感染 SARS-CoV-2 前一年内都曾使用过 CD20 单克隆抗体,其中两名患者还曾使用过布鲁顿酪氨酸激酶 (BTK) 抑制剂。这些患者的淋巴细胞数量明显偏低,B 细胞几乎耗竭。五名患者的血清 SARS-CoV-2 IgG 和 IgM 抗体检测结果均为阴性。在 6 个月的随访期间,经过抗病毒和 tix-cil 治疗后,没有一名患者再次感染 SARS-CoV-2 肺炎。总之,对于因 B 细胞耗竭而并发淋巴瘤的患者,抗病毒药物和 SARS-CoV-2 中和抗体对 SARS-CoV-2 肺炎有令人鼓舞的疗效,而且中和抗体还具有长达 6 个月的潜在预防效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BioMed Research International
BioMed Research International BIOTECHNOLOGY & APPLIED MICROBIOLOGY-MEDICINE, RESEARCH & EXPERIMENTAL
CiteScore
6.70
自引率
0.00%
发文量
1942
审稿时长
19 weeks
期刊介绍: BioMed Research International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies covering a wide range of subjects in life sciences and medicine. The journal is divided into 55 subject areas.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信